The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study

Table 2 Clinical Outcomes of COVID-19 Convalescent Plasma Therapy Versus Standard Care

Variable	CPT (n = 52)	Standard Care (n = 55)	P-value
14-day all-cause mortality, n (%)	8 (15.38)	47 (85.45)	< 0.001^a
14-day severe COVID-19 death, n (%)	7 (13.46)	47 (85.45)	< 0.001^a
28-day all-cause mortality, n (%)	8 (15.38)	47 (85.45)	< 0.001^a
28-day severe COVID-19 death, n (%)	7 (13.46)	47 (85.45)	< 0.001^a
Duration of supplemental oxygen (days); median (IQR)	5 (4–9)	15 (9.5–18)	< 0.001^b
Receiving mechanical ventilation, n (%)	44/52 (84.61)	47/55 (85.45)	0.903^a
Receiving high flow nasal cannula, n (%)	16/52 (30.77)	27/55 (49.08)	0.053^a
High-flow oxygen therapy; mask with bag, n (%)	11/52 (21.15)	39/55 (70.91)	< 0.001^a
Low-flow oxygen cannula, n (%)	21/52 (40.38)	21/55 (38.18)	0.816^a
Length of stay (Days); median (IQR)	10 (3–21)	7 (1–56)	< 0.001^b
WHO clinical progression scale < 4 on day 3 after admission	1 (1.92)	0 (0)	0.486^c
WHO clinical progression scale < 4 on day 5 after admission	6 (11.54)	0 (0)	0.027^c
WHO clinical progression scale < 4 on day 8 after admission	23 (44.23)	0 (0)	< 0.001^a
WHO clinical progression scale < 4 on day 14 after admission	38 (73.08)	2 (7.27)	< 0.001^a
Improvement of pneumonia from chest radiography on day 7	26/52 (50)	0/55 (0)	< 0.001^a
SpO₂ after weaning of supplemental oxygen n (%)	96 (96–99)	89.5 (73–98)	< 0.001^a
Number of patients success in weaning oxygen support	44/52 (84.6)	8/55 (14.5)	< 0.001^a

^aChi-square test
^bMann-Whitney U test
^cFisher’s exact test
CPT convalescent plasma therapy, SpO₂ oxygen saturation, IQR interquartile range, WHO World Health Organization

ISSN: 1476-0711